A superiority multicentric open-label randomised controlled trial has compared selective internal radiation therapy with Yttrium 90 (182 patients) versus sorafenib (178 patients) in patients with locally advanced HCC. Overall survival was not statistically different between the two groups (8.8 months for selective internal radiation therapy and 10 months for sorafenib, P=0.36). Less adverse events were observed in the group treated by selective internal radiation therapy.

(Chow PKH et al. – Journal of Clinical Oncology, 1 July 2018)

Read more